Boehringer Ingelheim Corporation Release: ASTHMA: New Phase 3 Data Show Tiotropium* Respimat® Effective Across Asthma Severities
3/3/2014 8:44:56 AM
SAN DIEGO--(BUSINESS WIRE)--For Media outside the U.S., Canada and UK.
Boehringer Ingelheim today announced new data from large scale, Phase III studies showing that once-daily tiotropium delivered via the Respimat® inhaler was effective and well tolerated in patients across asthma severities. These data were presented at the American Academy of Allergy, Asthma & Immunology (AAAAI) 2014 annual meeting in San Diego.
Help employers find you! Check out all the jobs and post your resume.